Benefitting from France's ageing population

(Full access for Members only)

Benefitting from France's ageing population

28 March 2023

In France, one in four inhabitants is now over 60 years of age. By 2040, this ratio will be nearly one in three. Many of these elderly French people will need a care home for some of their final years; thanks to longer life expectancies, this final period will only grow longer.

This demographic trend makes for steadily growing demand for care homes and similar facilities, a business with high barriers to entry.

The stock featured in this report gives you co-ownership in one of the leading care home providers in France. It's currently available at an unusually low valuation, because of the "ORPEA scandal" that rocked France's care home sector in 2022. However, even though this particular company was not implicated in the scandal at all, its stock lost 50% because investors sold off the entire sector.

The market should shortly start to differentiate between different operators. The company featured in this report is among the "good" ones, which was even recognised by the journalist who exposed ORPEA.

It's a high-quality growth stock with high insider ownership, a strong balance sheet, and a three-decade track record for double-digit growth rates.

Lo and behold, the company should leave this crisis stronger than before – which is why it has recently been buying back massive amounts of stock.

Not a Member yet? Sign up for a Membership - just USD 49/year.
Already a Member? Log into your account to download the report.

Most recent

Latest reports (for Members only)

Ukraine reconstruction: one stock to benefit

Ukraine reconstruction: one stock to benefit

If or when the war in Ukraine ends, this stock will likely become the focus of investor money pushing into the country.

Actinium-225, aka "the world's rarest drug"

Actinium-225, aka "the world's rarest drug"

This little-known Western European company could become the global market leader for supplying the uber-rare "Ac-225", a potent weapon to treat cancer.

Internet leader at a bargain price

Internet leader at a bargain price

If you missed buying Meta or Spotify in 2022, this global Internet leader is for you. One major investor is already on the case.